News coverage about Spring Bank Pharmaceuticals (NASDAQ:SBPH) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spring Bank Pharmaceuticals earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.9497929988698 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Spring Bank Pharmaceuticals (SBPH) traded up $0.04 on Wednesday, reaching $15.60. The company’s stock had a trading volume of 110,493 shares, compared to its average volume of 25,258. The stock has a market capitalization of $201.20, a PE ratio of -6.02 and a beta of 0.40. Spring Bank Pharmaceuticals has a fifty-two week low of $7.95 and a fifty-two week high of $18.93.
A number of brokerages have commented on SBPH. Cantor Fitzgerald set a $29.00 price target on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 16th. ValuEngine cut Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $28.00.
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.